A mong the hematopoietic cells, miR-150 is predominantly expressed in B, T, and natural killer cells through their development and maturation, except during the differentiation of naïve T cells into the effector Th1 and Th2 cells. [2] [3] [4] Importantly, miR-150-deficient mice lack lymphoid cell maturation and effector functions. 2, 4 In nonlymphoid lineages, miR-150 favors differentiation of megakaryocyte-erythrocyte progenitors to megakaryocytes at the expense of erythrocytes. 5 In determining cell fate, miR-150 targets multiple downstream targets, including MYB, FLT3, CBL, EGR2, DKC1, AKT2, Myb and Notch3.
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While miR-150 functions as a tumor suppressor in acute leukemia and lymphoma, its role in altering the behavior of the malignant CTCL cells is largely unknown. 6 Similar to data previously published by other groups, 7, 8 data in this study showed that miR-150 was significantly reduced in patients with advanced-stage CTCL who exhibited extensive nodal or visceral involvement. Two faces of ET: CALR and JAK2 Third, the Janus kinase (JAK) inhibitor ruxolitinib elicited responses in CALRmutated, hydroxyurea-refractory ET patients, similar to those observed in JAK2-mutated patients. 1 To establish the clinical implications of these molecular findings, Rotunno et al compared mutational subgroups of ET, 2 and
Rumi and colleagues compared cohorts of CALR-and JAK2-mutated ET to patients with polycythemia vera (PV). 1 Compared with JAK2-mutated ET, both groups found that CALR-mutated ET patients were more commonly male, demonstrated higher platelet counts, and lower leukocyte and hemoglobin levels (see figure) . 1,2 Individuals with PV exhibited higher leukocyte and hemoglobin values compared with CALR-and JAK2-mutated ET patients but lower platelet counts and serum erythropoietin levels.
1 Both analyses identified a lower incidence of thrombosis in CALR vs JAK2-mutated ET patients (see figure) , 1,2 but thrombosis rates were not different between PV and CALR and JAK2 mutations represent 2 disease spectrums in essential thrombocythemia whereby cases with mutated CALR are characterized by higher platelet levels, lower hemoglobin and leukocyte counts, and lower thrombosis risk compared with JAK2-mutated patients. Professional illustration by Debra T. Dartez.
JAK2-mutated ET. 1 Rotunno et al identified a 10-year cumulative incidence of thrombosis of 5.1% vs 14.5% in CALR-vs JAK2-mutated patients, respectively, 2 paralleling the 15-year cumulative thrombosis incidence of 10.5% vs 25.1% identified by Rumi et al. 1 The higher thrombosis rate in JAK2-mutated ET patients may be partly attributable to the hyperviscosity associated with higher hematocrit and leukocyte levels, the latter being a putative risk factor for thrombosis in MPNs. Evaluation of leukocyte and platelet activation, as well as hypercoagulability profiles, will lend further insight into this differential propensity for thrombosis.
The effect of mutational status on the clinical course of ET was evaluated in both studies and was also compared with PV. Although ET patients carrying a CALR mutation exhibited a better overall survival than PV patients, a nonsignificant trend 1 or no difference in survival 2 was found between CALR and JAK2-mutated ET patients. In contrast, a significant difference (P 5 .04) was observed in 10-year overall survival between these ET subgroups by Klampfl et al. 4 The 15-year cumulative incidence of secondary myelofibrosis was similar between CALR-and JAK2-mutated ET and PV, 1 but evolution to leukemia was lower for CALR-mutated ET patients compared with the other groups.
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Whereas a significant fraction of JAK2-mutated ET patients progressed to PV, none with a CALR mutation did so. 1 Consistent with prior data, the median JAK2 mutant allele burden was higher in ET patients who progressed to PV, as well as in post-PV/ET MF compared with the initial MPN. 1 These data reinforce that PV and JAK2-mutated ET form a continuum wherein phenotype and natural history are substantially influenced by JAK2 allele burden. While investigators decipher how CALR mutations contribute to MPN pathogenesis, it is clear that CALR will be quickly assimilated into World Health Organization diagnostic criteria for ET and PMF. Less clear is whether CALR mutation status will provide independent prognostic utility in scoring systems 10 used to estimate vascular risk and survival. Also, the effect of CALR mutant allele burden on clinical correlates remains untested. Looking forward, these observational studies provide a framework for assessing whether conventional therapies used broadly for ET (eg, aspirin for low-risk patients and hydroxyurea for high-risk individuals) are also appropriate for CALR-mutated patients who may exhibit lower-risk features. Conflict-of-interest disclosure: J.G. receives funding for administration of clinical trials, serves on an advisory board, and receives honoraria from Incyte, Inc. The remaining author declares no competing financial interests. n 1 H epcidin is the key iron hormone that regulates iron availability from 3 main sources: dietary absorption, red blood cell recycling, and body iron stores. 2 Hepcidin acts by inducing degradation of the principal iron exporter ferroportin, thereby blocking iron release into the bloodstream and leading to iron sequestration in enterocytes, macrophages, and hepatocytes. 2 Increases in iron levels stimulate hepcidin production to "turn off" further iron release into the circulation and to prevent iron excess. Inflammation also stimulates hepcidin production to limit iron accessibility to infectious organisms. Alternatively, when erythropoiesis is stimulated by anemia or hypoxia, hepcidin production is inhibited to "turn on" iron release into the circulation to support red blood cell production. Diseases of dysregulated hepcidin include hemochromatosis, in which too little hepcidin leads to iron overload, and the anemia of inflammation (also called anemia of chronic disease), in which too much hepcidin leads to iron-restricted erythropoiesis. 2 Hepcidin is mainly secreted by hepatocytes in the liver, where its expression is controlled by a variety of signals. One central signaling pathway that controls hepcidin production is the bone morphogenetic protein (BMP)-sons of mothers against decapentaplegic (SMAD) signaling pathway through the coreceptor hemojuvelin 3 and the ligand BMP6. 4 This pathway is not only essential for hepcidin regulation by iron, but its activity is also
